29 September 2025

$250K PLACEMENT AND NEW $1.4M RDTI LOAN FACILITY

- **Placement completed to a new strategic, sophisticated investor, raising $250,000.**
- **Placement of shares at $0.022 (2.2 cents) and 1 attaching listed option expiring 30 Dec28 for every 2 shares subscribed, consistent with the recently completed Rights Issue Offer.**
- **Represents a premium of 22.2% to the closing price of $0.018 on 26 September 2025 and a premium of 7.7% to the 15-day VWAP to 26 September 2025.**
- **New $1,400,000 RDTI Loan Facility entered into with No Bull Health Pty Ltd, a related party of the Company's largest shareholder, Harmil Angel Investments.**
- **Initial drawdown of $480,000 completed, with shareholder approval to be sought at the Company's upcoming AGM for the Loan to be secured against eligible R&D expenditure.**
- **Funds raised from the Placement and RDTI Loan initial drawdown to be deployed to compliment the consumer market pivot.**

HITIQ Limited (**ASX: HIQ**) (**HITIQ** or the **Company**) advises it has completed a $250,000 placement and entered into a new RDTI loan facility to raise additional capital to support the ongoing consumer market commercialisation of its concussion management technology.

<u>$250,000 Placement</u>

The Company has placed 11,363,637 ordinary shares (**Placement Shares**) at an issue price of $0.022 per Placement Share (**Placement**) to a sophisticated and professional investor, raising $250,000 (before costs).

Pricing and terms of the Placement are consistent with those of the recently completed Rights Issue Offer as announced on 1 May 2025. No Lead Manager was appointed for the Placement.

The price of the Placement Shares represents a premium of 22.2% to the closing price of $0.018 on 26 September 2025 and a premium of 7.7% to the 15-day VWAP to 26 September 2025.

The terms of the Placement include 5,681,819 attaching new options (exercisable at $0.022 and expiring on 30 December 2028), representing one attaching new option for every two shares issued under the Placement (**Placement Options**).

The issue of the Placement Shares and Options will be completed under the Company's ASX Listing rule 7.1 capacity and are expected to be issued on or before 30 September 2025.

$1,400,000 RDTI Loan

The Company has recently reviewed its loan facility secured against eligible research and development expenditure, with a focus on cost, quantum and timing of timing of access to funding. Following the review, the Company has entered into a new $1,400,000 loan facility (**RDTI Loan**) with No Bull Health Pty Ltd (**No Bull**), a related party of the Company's largest shareholder, Harmil Angel Investments (**Harmil**). Harmil Is a private investment vehicle of former NRL player, Adam MacDougall, and have been a cornerstone investor of the Company since 2023. The RDTI Loan will initially be unsecured, with shareholder approval to be sought at the Company's upcoming AGM for a Specific Security Agreement to be entered into with No Bull such that the RDTI Loan Is secured against forecast R&D expenditure, which is consistent for such a facility.

The RDTI Loan is on an arms-length basis, with standard terms and conditions for a facility of this type, including:

- Loan Amount: $1,400,000
- Maturity Date: 365 days from the date of the Agreement
- Relevant Financial Year: 2026
- Final Tax Claim Date: 30 June 2026
- Interest Rate: 12% per annum
- Application Fee: $5,500.00 (Incl GST)

An Initial drawdown of $480,000 has been completed under the RDTI Loan.

HITIQ's Executive Chairman, Earl Eddings said, "We are pleased to welcome this new sophisticated investor to our register, with whom we were endeavoring to incorporate their investment in the Shortfall Placement of the recent Rights Issue Offer. We are also delighted to extend our strong relationship with Harmil with the new $1.4m RDTI Loan, whose wealth of experience and strategic insights of consumer products businesses has been extremely valuable to HITIQ."

The release of this announcement was authorised by the Board.

- Ends -

For more information:
Shareholders: investors@hitiq.com

About HITIQ

To learn more about HITIQ's Impact IQ technology please visit hitiq.com

